A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.

Saved in:
Bibliographic Details
Title: A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
Authors: Manda S; Arizona Oncology, The US Oncology Network, Tucson, Arizona, USA., Anz BM 3rd; Tennessee Oncology, Chattanooga, Tennessee, USA., Benton C; Rocky Mountain Cancer Centers, The US Oncology Network, Englewood, Colorado, USA., Broun ER; Oncology Hematology Care Inc, Cincinnati, Ohio, USA., Yimer HA; Texas Oncology/USON, Tyler, Texas, USA., Renshaw JS; Texas Oncology - San Antonio Medical Center, The US Oncology Network, San Antonio, Texas, USA., Geils G Jr; Charleston Oncology, Charleston, South Carolina, USA., Berdeja J; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, Tennessee, USA., Cruz J; Methodist Physicians Texas Transplant Specialists, San Antonio, Texas, USA., Melear JM; Texas Oncology - Austin Midtown, The US Oncology Network, Austin, Texas, USA., Fanning S; Prisma Health Cancer Institute, Greenville, South Carolina, USA., Fletcher L; Willamette Valley Cancer Institute and US Oncology Research Center, Eugene, Oregon, USA., Li Y; AbbVie, Inc, North Chicago, Illinois, USA., Duan Y; AbbVie, Inc, North Chicago, Illinois, USA., Werner ME; AbbVie, Inc, North Chicago, Illinois, USA., Potluri J; AbbVie, Inc, North Chicago, Illinois, USA., Pai MV; AbbVie, Inc, North Chicago, Illinois, USA., Donnellan WB; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, Tennessee, USA.
Source: Hematological oncology [Hematol Oncol] 2024 May; Vol. 42 (3), pp. e3274.
Publication Type: Journal Article; Clinical Trial, Phase III; Multicenter Study
Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8307268 Publication Model: Print Cited Medium: Internet ISSN: 1099-1069 (Electronic) Linking ISSN: 02780232 NLM ISO Abbreviation: Hematol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38711253
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Manda+S%22">Manda S</searchLink>; Arizona Oncology, The US Oncology Network, Tucson, Arizona, USA.<br /><searchLink fieldCode="AU" term="%22Anz+BM+3rd%22">Anz BM 3rd</searchLink>; Tennessee Oncology, Chattanooga, Tennessee, USA.<br /><searchLink fieldCode="AU" term="%22Benton+C%22">Benton C</searchLink>; Rocky Mountain Cancer Centers, The US Oncology Network, Englewood, Colorado, USA.<br /><searchLink fieldCode="AU" term="%22Broun+ER%22">Broun ER</searchLink>; Oncology Hematology Care Inc, Cincinnati, Ohio, USA.<br /><searchLink fieldCode="AU" term="%22Yimer+HA%22">Yimer HA</searchLink>; Texas Oncology/USON, Tyler, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Renshaw+JS%22">Renshaw JS</searchLink>; Texas Oncology - San Antonio Medical Center, The US Oncology Network, San Antonio, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Geils+G+Jr%22">Geils G Jr</searchLink>; Charleston Oncology, Charleston, South Carolina, USA.<br /><searchLink fieldCode="AU" term="%22Berdeja+J%22">Berdeja J</searchLink>; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, Tennessee, USA.<br /><searchLink fieldCode="AU" term="%22Cruz+J%22">Cruz J</searchLink>; Methodist Physicians Texas Transplant Specialists, San Antonio, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Melear+JM%22">Melear JM</searchLink>; Texas Oncology - Austin Midtown, The US Oncology Network, Austin, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Fanning+S%22">Fanning S</searchLink>; Prisma Health Cancer Institute, Greenville, South Carolina, USA.<br /><searchLink fieldCode="AU" term="%22Fletcher+L%22">Fletcher L</searchLink>; Willamette Valley Cancer Institute and US Oncology Research Center, Eugene, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Li+Y%22">Li Y</searchLink>; AbbVie, Inc, North Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Duan+Y%22">Duan Y</searchLink>; AbbVie, Inc, North Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Werner+ME%22">Werner ME</searchLink>; AbbVie, Inc, North Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Potluri+J%22">Potluri J</searchLink>; AbbVie, Inc, North Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Pai+MV%22">Pai MV</searchLink>; AbbVie, Inc, North Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Donnellan+WB%22">Donnellan WB</searchLink>; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, Tennessee, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228307268%22">Hematological oncology</searchLink> [Hematol Oncol] 2024 May; Vol. 42 (3), pp. e3274.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase III; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>8307268 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1099-1069 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2202780232%22">02780232 </searchLink><i>NLM ISO Abbreviation: </i>Hematol Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38711253
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/hon.3274
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e3274
    Titles:
      – TitleFull: A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Manda S
      – PersonEntity:
          Name:
            NameFull: Anz BM 3rd
      – PersonEntity:
          Name:
            NameFull: Benton C
      – PersonEntity:
          Name:
            NameFull: Broun ER
      – PersonEntity:
          Name:
            NameFull: Yimer HA
      – PersonEntity:
          Name:
            NameFull: Renshaw JS
      – PersonEntity:
          Name:
            NameFull: Geils G Jr
      – PersonEntity:
          Name:
            NameFull: Berdeja J
      – PersonEntity:
          Name:
            NameFull: Cruz J
      – PersonEntity:
          Name:
            NameFull: Melear JM
      – PersonEntity:
          Name:
            NameFull: Fanning S
      – PersonEntity:
          Name:
            NameFull: Fletcher L
      – PersonEntity:
          Name:
            NameFull: Li Y
      – PersonEntity:
          Name:
            NameFull: Duan Y
      – PersonEntity:
          Name:
            NameFull: Werner ME
      – PersonEntity:
          Name:
            NameFull: Potluri J
      – PersonEntity:
          Name:
            NameFull: Pai MV
      – PersonEntity:
          Name:
            NameFull: Donnellan WB
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2024 May
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1099-1069
          Numbering:
            – Type: volume
              Value: 42
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Hematological oncology
              Type: main
ResultId 1